Ciel Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
- Paid Up Capital ₹ 2.17 Cr
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 4.60 Cr
- Revenue Growth 88.35%
- Profit Growth 382.28%
- Ebitda -418.97%
- Net Worth 159.89%
- Total Assets 136.53%
About Ciel Pharma
Ciel Pharma Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 June 2011 and has a history of 13 years and seven months. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.17 Cr.
The company currently has active open charges totaling ₹4.60 Cr.
Muneesh Dogra and Garima Tiwari serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233UP2011PTC045378
-
Company No.
045378
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Jun 2011
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Ciel Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Muneesh Dogra
|
Director | 17-Jan-2020 | Current |
|
Garima Tiwari
|
Director | 01-Jan-2020 | Current |
Financial Performance of Ciel Pharma.
Ciel Pharma Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 88.35% increase. The company also saw a substantial improvement in profitability, with a 382.28% increase in profit. The company's net worth Soared by an impressive increase of 159.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ciel Pharma?
In 2018, Ciel Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Cielprints LlpMuneesh Dogra and Garima Tiwari are mutual person
Charges (Loans)
₹4.60 Cr
₹0
Charges Breakdown by Lending Institutions
- Sidbi : 4.40 Cr
- Hdfc Bank Limited : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 May 2022 | Sidbi | ₹4.40 Cr | Open |
| 11 Nov 2020 | Hdfc Bank Limited | ₹2.04 M | Open |
How Many Employees Work at Ciel Pharma?
Unlock and access historical data on people associated with Ciel Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ciel Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ciel Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
